SUGGESTED FORMULATION. Expiry Date. Lot Number. Ingredient Listing Qty. Unit NDC # Supplier

Similar documents
CHAPTER CONSULTING PHARMACIST REGULATIONS FOR LONG-TERM CARE FACILITIES (SKILLED, INTERMEDIATE, AND BASIC CARE)

Health Professions Act BYLAWS SCHEDULE F. PART 2 Hospital Pharmacy Standards of Practice. Table of Contents

Licensed Pharmacy Technician Scope of Practice

Veterinary Compounding

IACP Comparison of 503A and 503B The Drug Quality and Security Act of 2013

BRIEFING 7 LABELING DEFINITION

ExCPT Certified Pharmacy Technician (CPhT) Detailed Test Plan* 100 scored items, 20 pretest items Exam time: 2 hours 10 minutes

Professional Standards and Guidance for the Sale and Supply of Medicines

By Lawrence A. Trissel, B.S., R.Ph., FASHP. Modified from the original presentation March 9, 2006

The following Good Compounding Practices (GCPs) are meant to apply only to the compounding of drugs by State-licensed pharmacies.

Draft guidance for registered pharmacies preparing unlicensed medicines

It's in the details. JOST MINERAL GUIDE

NOTE: FOR PROJECTS REQUIRING CONTRACTOR MIX DESIGN, THE DESIGN PROCEDURES ARE SPECIFIED IN THE SPECIAL PROVISIONS OF THE CONTRACT.

DIVISION OF CORPORATIONS, BUSINESS AND PROFESSIONAL P.O. BOX JUNEAU, ALASKA ALASKA STATE BOARD OF PHARMACY

FAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS. THIRAM tetramethylthiuram disulphide

8. A listing of the medications that are approved for use within a system is a/an A) inventory. B) wholesaler. C) database. D) formulary.

ASHP Technical Assistance Bulletin on Compounding Nonsterile Products in Pharmacies

Quality Systems Appropriate for Extemporaneously Prepared Early Phase Clinical Trial Materials. Agenda Topics for Discussion

Educational Outcomes for Pharmacy Technician Programs in Canada

Legal and Ethical Veterinary Compounding. Scott D. Stanley, Ph.D., Professor University of California, Davis School of Veterinary Medicine

Guidance for Industry

Change to read: 1160 PHARMACEUTICAL CALCULATIONS IN PRESCRIPTION COMPOUNDING PHARMACY PRACTICE 1S (USP38)

Vinod et al., ARPB, 2013; Vol 3 (II) ISSN

A Stability Program for the Distribution of Drug Products

FAO SPECIFICATIONS FOR PLANT PROTECTION PRODUCTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS

EMPLOYER BASED QUALIFIED PHARMACY TECHNICIAN EXAMS GUIDANCE

POWDER PROPERTIES LABORATORY

[See Rules 74,74-A, 74-B, 78 and 78-A] A. SUBSTANCES OTHER THAN PARENTERAL IN PREPARATIONS IN GENERAL

PL 17871/0208 UKPAR TABLE OF CONTENTS

GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES

STARCH Application Data

CHAPTER 6 PROCUREMENT AND SUPPLY OF PHARMACEUTICAL PRODUCTS IN THE PUBLIC AND PRIVATE MEDICAL SECTORS

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry

247 CMR: BOARD OF REGISTRATION IN PHARMACY

Commentary USP 36-NF 31. Excerpt Related to General Chapter <17> Prescription Container Labeling

S.3.6. BULK DENSITY AND TAPPED DENSITY OF POWDERS. Final text for addition to The International Pharmacopoeia

COURSE OUTLINE. PROGRAM: Pharmacy Technician Bridging Education Program. COURSE NAME: Management of Drug Distribution. COURSE DURATION: 39 hrs.

Pharmacy Technician Web Based Calculations Review

Health Canada Manufacturing and Compounding Drug Products in Canada: A Policy Framework Guidelines for P.E.I. Community and Hospital Pharmacists

Chapter. History and Traditional Technician Roles

03 PHARMACY TECHNICIANS

Pharmacy Program Pre-Test

General Chapter <800> Open Microphone Web Meeting

Dry Powders, Capsules, and Lozenges

Guidelines for Compounding Practices

Calibration & Preventative Maintenance. Sally Wolfgang Manager, Quality Operations Merck & Co., Inc.

OMCL Network of the Council of Europe QUALITY MANAGEMENT DOCUMENT

BOARD OF PHARMACY DIVISION 41 OPERATION OF PHARMACIES (RETAIL AND INSTITUTIONAL DRUG OUTLETS) CONSULTING PHARMACISTS AND OPERATION OF DRUG ROOMS

Career-Technical Credit Transfer (CT)² Pharmacy Technician Career Technical Assurance Guide (CTAG) August 26, 2012

RECONSTITUTING MEDICATIONS: HOW TO FLUFF UP MEDICATIONS

The Analytical Balance

Standards of Practice for Pharmacists and Pharmacy Technicians

Health Professions Act BYLAWS SCHEDULE F. PART 3 Residential Care Facilities and Homes Standards of Practice. Table of Contents

Lacidipine 2 mg Film-Coated Tablets PL 08553/0502. Lacidipine 4 mg Film-Coated Tablets PL 08553/0503. UK Public Assessment Report

PROCESS VALIDATION OF TABLETS: AN OVERVIEW

sugar sugar products for your sweet success

If you have any questions, please do not hesitate to contact us. We look forward to meeting you!

The importance of normalisation when comparing tablet properties

Implementing New USP Chapters for Analytical Method Validation

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA PARACETAMOL ORAL SUSPENSION (September 2010)

THE PHARMACEUTICAL INDUSTRY

Overview of the BCBSRI Prescription Management Program

Florida Department of Education Curriculum Framework PSAV

Particle size measurement of lactose for dry powder inhalers

INSTITUTIONAL POLICY AND PROCEDURE (IPP) Department: Manual: Section: EFFECTIVE DATE REVIEW DUE REPLACES NUMBER NO. OF PAGES

Safe IV Compounding Procedures: The Release of ISMP Guidelines

Local Enhanced Service Specification for the Supply of Pharmaceutical Services to Care Homes through Community Pharmacy

GUIDELINES ON COMPOUNDING OF MEDICINES. March PharmBA

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT

Manual of Instructions

Annex 9 Guide to good storage practices for pharmaceuticals 1

CONNECTICUT. Downloaded January D8T. CHRONIC AND CONVALESCENT NURSING HOMES AND REST HOMES WITH NURSING SUPERVISION

METHOD OF PREPARATION: 1. Calculate the required quantity of each ingredient for the total amount to be prepared.

Minnesota Board of Pharmacy. Guidance on the Compounding of Veterinary Products Approved: March 4, 2015

THE DRUGS AND COSMETICS RULES, 1945

How To Understand The Pharmacology Of The Pharmaceutical Industry

A Pharmacy Pharmacist, Ms B. A Report by the Health and Disability Commissioner. (Case 04HDC13191)

REGULATION 3 PHARMACY TECHNICIANS

Position Classification Standard for Pharmacy Technician Series, GS-0661

Customized Nutritional Solutions For Laboratory Animals

FOR PLANT PROTECTION PRODUCTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS

IAC 12/12/12 Pharmacy[657] Ch 5, p.1 CHAPTER 5 PHARMACY SUPPORT PERSONS

Bill Mixon, RPh, MS Senior Associate Gates Healthcare Associates

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER

NH Laws / Rules Regarding Limited Retail Drug Distributors

UW School of Dentistry Comprehensive Medication Policy

Policy for the Storage and Administration of Medication in Custody Suites

A safe return and reuse protocol in the community pharmacy setting may include, but is not limited to, the following elements:

Process Validation Protocol (Reference: SOP )

Overview of the BCBSRI Prescription Management Program

Pharmacist, Mr C A Pharmacy Company. A Report by the Health and Disability Commissioner. (Case 04HDC10718)

Food and Drug Administration, HHS Pt. 212

From the Text. Definitions. Definitions. Definitions. Definitions. RSPT 2217 Basic Concepts & Principles. RSPT Basic Concepts

Billing with National Drug Codes (NDCs) Frequently Asked Questions

Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products

Eight Important Principles For Managing Prescription Medications In the Athletic Training Room

RESOLUTION-RDC Nr- 48, OF OCTOBER 6, 2009

Microbiology and Auditing. Don Singer

Standard Test 1. SCOPE Description of Test

Review of Maine Pharmacy Rules. An update of new rules adopted 12/11/2013

Transcription:

11/22/2016; Page 1 Note: Calcium Citrate Tetrahydrate 711 mg is equivalent to Calcium 150 mg; Magnesium Citrate (Tribasic) 619 mg is equivalent to Magnesium 100 mg; Zinc Sulfate (Monohydrate) 34.25 mg is equivalent to Zinc 12.5 mg. SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Calcium Citrate Tetrahydrate, USP 21.330 g Magnesium Citrate (Tribasic), USP 18.570 g Zinc Sulfate (Monohydrate), USP 1.028 g Mango Flavor (Powder) 1.050 g Raspberry Flavor (Powder) 0.900 g Vanillin Flavor (Powder) 0.300 g Stevia Powder 0.225 g Medisca FizzMix Base SPECIAL PREPARATORY CONSIDERATIONS Ingredient-Specific Information TBD Lot Number Expiry Date Hygroscopic (protect from moisture whenever possible): FizzMix Base, Stevia Powder Suggested Preparatory Guidelines Non-Sterile Preparation Sterile Preparation Processing Error / Testing Considerations: Special Instruction: To account for processing errors and considerations during preparation, it is suggested to measure an additional 1 to 3% of the required quantities of ingredients. Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn. This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

11/22/2016; Page 2 SUGGESTED PREPARATION (for 30 x 7.5 ml pouches) Weigh and / or measure the following ingredients when appropriate: Ingredient Listing Qty. Unit Multiplication factor (*) : Processing Error Qty. to measure Calcium Citrate Tetrahydrate, USP 21.330 g Magnesium Citrate (Tribasic), USP 18.570 g Zinc Sulfate (Monohydrate), USP 1.028 g Mango Flavor (Powder) 1.05 g Raspberry Flavor (Powder) 0.90 g Vanillin Flavor (Powder) 0.30 g Stevia Powder 0.225 g Medisca FizzMix Base TBD * Takes into account increased batch size conversions and density conversions, if required. Weigh / measure just prior to use. 1. FizzMix Base requirements for 30 7.5 ml Bins Preparatory Instruction A. Calculate the amount of FizzMix Base required for the batch. Refer to attached appendix for details. 2. Powder preparation: A. Pass the FizzMix Base through a 30 mesh sieve and weigh the required quantity (quantity determined in appendix (I)). B. By geometric addition, combine and triturate the following ingredients together to form a fine, homogeneous powder blend: -Calcium Citrate Tetrahydrate -Magnesium Citrate (Tribasic) -Zinc Sulfate (Monohydrate) -Mango Flavor (Powder) -Raspberry Flavor (Powder) -Vanillin Flavor (Powder) -Stevia Powder C. By geometric addition, combine and mix, using a manual tumbler mixer (DO NOT TRITURATE) the following ingredients together to form a homogeneous powder blend: -Sieved FizzMix Base (Step 2A) -Homogeneous powder blend (Step 2B)

11/22/2016; Page 3 Suggested 3. Product transfer: Fill each of 30 7.5 ml bins with the homogeneous powder blend (Step 2C). Do not tap the device on the bench while filling as the API(s) and FizzMix Base have been calibrated to determine their BULK DENSITY. 4. Validation technique: The final weight of each bin (not including the bin shell) should fall between 90 and 110% of the theoretically calculated weight, in accordance to USP 795 guidelines. The theoretically calculated weight can be determined by adding the amount in appendix (G) + 1.447 g together. 5. Product transfer: Transfer the contents of each filled bin into the specified dispensing container (see Packaging Requirements ). SUGGESTED PRESENTATION Estimated 6 months, as per USP*. Beyond-Use Date Packaging Requirements - Pack into 100 mm 80 mm moisture barrier bags and put into suitable container. Auxiliary Labels 1 Use as directed. Do not exceed prescribed dose. 2 Keep out of reach of children. 5 Keep in a dry place. 4 Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use. 3 Keep at room temperature (20 C 23 C). 6 Discard container after use. Pharmacist Instructions Add any auxiliary labels specific to the active ingredients to the dispensing container as deemed necessary. Patient Instructions Contact your pharmacist in the event of adverse reactions. Note: Disperse one pouch into 6 to 8 ounces of water and mix until homogeneous before taking the mixture. * The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.

11/22/2016; Page 4 REFERENCES 1. Powders and Granules. In: Allen, LV, Jr. The Art, Science and Technology of Pharmaceutical Compounding Fourth Edition. American Pharmaceutical Association; 2012: 141. 2. Calcium Citrate. In: Sweetman SC, ed. Martindale: The Complete Drug Reference, 36 th Edition. London, England: The Pharmaceutical Press; 2009: 1675. 3. Magnesium Citrate. In: Sweetman SC, ed. Martindale: The Complete Drug Reference, 36 th Edition. London, England: The Pharmaceutical Press; 2009: 1743. 4. Zinc Sulfate. In: Sweetman SC, ed. Martindale: The Complete Drug Reference, 36 th Edition. London, England: The Pharmaceutical Press; 2009: 1999. 5. Calcium Citrate (Monograph). In: O Neil MJ. The Merck Index 15 th Edition. Whitehouse Station, NJ: Merck & Co, Inc.; 2013: #1663. 6. Magnesium Citrate (Monograph). In: O Neil MJ. The Merck Index 15 th Edition. Whitehouse Station, NJ: Merck & Co, Inc.; 2013: #5727. 7. Zinc Sulfate (Monograph). In: O Neil MJ. The Merck Index 15 th Edition. Whitehouse Station, NJ: Merck & Co, Inc.; 2013: #10359. 8. Calcium Citrate (Monograph). United States Pharmacopeia XXXIX / National ry 34. Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 2874. 9. Magnesium Citrate (Monograph). United States Pharmacopeia XXXIX / National ry 34. Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 4651. 10. Zinc Sulfate (Monograph). United States Pharmacopeia XXXIX / National ry 34. Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 6429. 11. USP <795>. United States Pharmacopeia XXXIX / National ry 34. Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 617. DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.

11/22/2016; Page 1 Appendix Calculating the quantity of excipient required for the batch Procedure 1. Bin filling: a. For each ingredient powder below, determine the average bulk bin fill weight by filling and weighing two TARED BINS. Do not forget to divide the total weight by 2 to obtain an average bulk bin fill weight. Also, crush and triturate the ingredient first if required in formulation (DO NOT TRITURATE THE BASE). SIEVE THE BASE AND API BEFORE CALIBRATION. DO NOT TAP THE BASE OR THE API. Plug each amount into Step 2, column B. 2. Volume Percent Occupied: Column A Column B Column C Quantity Required Average bulk bin A/B x 100 equals Ingredients per bin fill weight percent filled a. Calcium Citrate Tetrahydrate 0.711 g g % b. Magnesium Citrate (Tribasic) 0.619 g g % c. FizzMix Base g d. Total (add column C together) % (D) 3. Calculate the quantity of FizzMix Base required for the batch: a. Percent of FizzMix Base required = 100% (D) % (E) b. Average bulk bin fill weight of FizzMix Base (from column B, Step 2c): g (F) c. Quantity of FizzMix Base required per bin = [(E) 100 (F)] (0.117 g)* g (G) *[Quantity of Zinc Sulfate, Flavors and Sweetener per bin] d. Total Quantity of FizzMix Base required for the batch = 30 bins (G) g (H) e. Total quantity of FizzMix Base plus processing error = (H) 1.01-1.03 g (I) DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.